Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model
- 1 March 2007
- journal article
- research article
- Published by Elsevier BV in Laboratory Investigation
- Vol. 87 (3), 251-260
- https://doi.org/10.1038/labinvest.3700515
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Met, the Hepatocyte Growth Factor Receptor, Localizes to the Nucleus in Cells at Low DensityCancer Research, 2006
- Quantitative In situ Analysis of β-Catenin Expression in Breast Cancer Shows Decreased Expression Is Associated with Poor OutcomeCancer Research, 2006
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)JNCI Journal of the National Cancer Institute, 2005
- Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survivalProceedings of the National Academy of Sciences of the United States of America, 2005
- X-TileClinical Cancer Research, 2004
- Tissue microarray‐based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptorsCancer, 2003
- HGF/SF‐met signaling in the control of branching morphogenesis and invasionJournal of Cellular Biochemistry, 2003
- Automated subcellular localization and quantification of protein expression in tissue microarraysNature Medicine, 2002
- Tissue Microarrays for Rapid Linking of Molecular Changes to Clinical EndpointsThe American Journal of Pathology, 2001
- Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland.The Journal of cell biology, 1995